I just spoke to Mr. Peacock, who is involved in IR at Vaso. Altho he was appropriately vague regarding sales, he did say that they were on schedule and increasing since the research was announced. I also, and this is especially for Don, asked him to compare Vaso with Cardiomedics. Again he was not inclined to disparage Cardio, but emphasized that Vaso has presented data on efficacy and this is critical in a highly regulated industry. He did say several of the unfavorable comparisons touted by Cardio were not accurate.
More importantly, IMO, the market for the product is, I think, appx 4 million, and each unit can handle 35-40 patients each annually. My concern was the limit of the market.
My personal conclusion is we're in a good thing, but we need the ol' virtue of patience.
good investing--fred |
